Drug Trial Radar · NCT00907387
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
Last checked: Nov 19, 2026Latest source record: Jan 17, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
Apr 2009
Primary completion
Oct 2009
Study completion Oct 2009
Sponsor
- Lead sponsor
- Revance Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 22, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of RT001 to treat moderate to severe lateral canthal lines in adults and duration of effect.
Conditions
- Lateral Canthal Lines
Interventions
RT001Drug
Dose A RT001
RT001Drug
Dose B RT001
PlaceboOther
Dose C Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- The number of subjects classified as exhibiting improvement via the Investigator Global Assessment at Rest from Baseline (Day 0) to Day 28Time frame: Day 28
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Total Skin & Beauty Dermatology Center
Birmingham, Alabama
Richard G. Glogau, Inc.
San Francisco, California
Dermatology Research Institute, LLC
Coral Gables, Florida
SkinCare Physicians, Inc.
Chestnut Hill, Massachusetts
Skin Specialists, PC
Omaha, Nebraska
Head and Neck Surgical Group
New York, New York
Aesthetic Plastic Surgery
New York, New York
Dermatology Surgery and Laser Center
White Plains, New York
Suzanne Bruce & Associates / The Center for Skin Research
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.